CN109010300A - A kind of Amisulpride piece and preparation method thereof - Google Patents
A kind of Amisulpride piece and preparation method thereof Download PDFInfo
- Publication number
- CN109010300A CN109010300A CN201811245257.8A CN201811245257A CN109010300A CN 109010300 A CN109010300 A CN 109010300A CN 201811245257 A CN201811245257 A CN 201811245257A CN 109010300 A CN109010300 A CN 109010300A
- Authority
- CN
- China
- Prior art keywords
- amisulpride
- piece
- hydroxypropyl methylcellulose
- preparation
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Amisulpride pieces, including following each component and its weight percentage: Amisulpride 60-70%, lactose 4-10%, microcrystalline cellulose 15-20%, sodium carboxymethyl starch 3-5%, hydroxypropyl methylcellulose 2-3%, magnesium stearate 0.1-0.5%, additive 0.5-1%, methoxy polyethylene glycol acrylate 1-3%, magnesium chloride 0.2-0.5%.The Amisulpride tablet stability obtained using raw material and method of the invention is good, and quick can must dissolve out, and improves drug safety and validity, avoids the incidence of adverse reaction.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, and in particular to a kind of Amisulpride piece and preparation method thereof.
Background technique
Amisulpride is a kind of atypical antipsychotics, is used for class paranoiac process schizophrenia, acute
The treatment of absurd Rui type mental disease, it can also be used to treat schizoid defect state, remaining spiritual disease-process and with
Blunt holddown.Amisulpride is usually administered orally with the tablet form that every tablet amounts are 100,200 and 400 milligrams.So
And during acute psychotic episode, the oral daily dosage of Amisulpride often improves, and can reach 1200 mg/days.Cause
This, must swallow several pieces tablets using the patient that Amisulpride is treated daily.
Due to the special pathological state of patient, and active constituent Amisulpride taste is very bitter, to correctly fixed in accordance with doctor's advice
When take a large amount of tablets and can meet difficulty, or even show significant uncommunicative, influence patient medication compliance；Therefore
The sensory issues of Amisulpride oral preparation in the urgent need to address.Amisulpride slightly soluble in water, but clinical requirement drug is quick
Dissolution, rapid-onset this requires improving drug dissolution using suitable prescription and technique in preparation production, and use existing
The Amisulpride piece that is prepared of method be difficult to reach Fast Stripping.The effect of rapid-onset, and obtained tablet is unstable
It is fixed, it is easily broken, the disintegration time limited of tablet is longer, cannot reach ideal requirement.
Number of patent application CN1842331A discloses a kind of Amisulpride solid composite medicament, comprising by lipid-coated and
Amisulpride particle that the coating of polymer coating is coated and at least one it is suitable for can pharmaceutically connecing for dispersion administration in mouth
The excipient composition received.The method preparation Amisulpride pharmaceutical composition be the particle containing Amisulpride is wrapped up, and
Specification is very big, and it is difficult to be made into dispersible tablet in mouth, it is difficult to achieve the effect that Fast Stripping, rapid-onset.
Number of patent application CN201710118831.2 discloses a kind of Amisulpride tablet and preparation method thereof, the tablet packet
Containing bulk pharmaceutical chemicals and auxiliary material, the improvement is that the tablet surface carries out film coating using film coating pre-mix dose, it is described
Film coating pre-mix dose includes Opadry gastric solubility coating powder and corrigent.The Amisulpride tablet of the method preparation is unstable,
It is easily broken, is unfavorable for transporting and saves, and the disintegration time limited of tablet is long, ideal requirement of arriving.
Summary of the invention
The purpose of the present invention is overcome the deficiencies of the prior art and provide a kind of Amisulpride piece and preparation method thereof.
The present invention provides a kind of Amisulpride pieces, including following each component and its weight percentage: Amisulpride 60-
70%, lactose 4-8%, microcrystalline cellulose 15-20%, sodium carboxymethyl starch 3-5%, hydroxypropyl methylcellulose 1-3%, magnesium stearate
0.1-0.5%, additive 0.5-1%, methoxy polyethylene glycol acrylate 1-3%, magnesium chloride 0.2-0.5%, coating powder 2-
3%.
Preferably, including following each component and its weight percentage: Amisulpride 63%, lactose 8%, microcrystalline cellulose
15%, sodium carboxymethyl starch 4%, hydroxypropyl methylcellulose 2%, magnesium stearate 0.3%, additive 0.8%, methoxy poly (ethylene glycol)
Acrylate 2.5%, magnesium chloride 0.4%, coating powder 3%.
Preferably, the additive includes following each component and its weight percentage: Aspartame 10-15%, essence
40-45%, sodium chloride 40-50%.
Preferably, the essence is orange taste essence or honey peach taste essence.
The present invention also provides a kind of preparation methods of Amisulpride piece, comprising the following steps:
1) raw material is weighed in proportion, and Amisulpride, lactose, microcrystalline cellulose, sodium carboxymethyl starch and additive are mixed
Obtain mixture；
2) hydroxypropyl methylcellulose aqueous solution and methoxy polyethylene glycol acrylate are added into mixture, after mixing
Wet granulation, particle drying obtained cross 20-30 mesh；
3) magnesium stearate and magnesium chloride are sequentially added into the particle after drying, carries out tabletting after mixing, obtained ammonia sulphur
Must sharp plain piece be coated, obtain Amisulpride piece.
Preferably, the mass percentage concentration of hydroxypropyl methylcellulose aqueous solution described in step 2) is 5-6%.
Preferably, the preparation method of the hydroxypropyl methylcellulose aqueous solution are as follows: by the suitable boiling water of hydroxypropyl methylcellulose
Then stirring and dissolving is added cold water and the hydroxypropyl methylcellulose aqueous solution that mass percentage concentration is 5-6% is made.
Preferably, the method for the step 3) coating are as follows: be dissolved in water to obtain mass concentration to be 10-15%'s by coating powder
Coating solution is coated Amisulpride plain piece in high-efficiency coating machine.
Preferably, the coating powder is Opadry gastric solubility coating powder.
The present invention is coated the Amisulpride plain piece after tabletting, can be further improved the stability of tablet, and energy
It covers the bitter taste of Amisulpride to a certain extent, is conducive to patient's medication.
The Amisulpride piece being prepared using existing raw material and method is difficult to reach Fast Stripping, the work of rapid-onset
With, and obtained tablet is unstable, is easily broken, and the disintegration time limited of tablet is longer, cannot reach ideal requirement.The application
Inventor methoxy polyethylene glycol acrylate and magnesium chloride are added on the basis of existing raw material, by the study found that
The Amisulpride piece arrived is stablized, and quick can must dissolve out, rapid-onset.
The addition sequence of each raw material of strict control of the present invention, and hydroxypropyl methylcellulose is first made aqueous solution, then with contain
The mixture and methoxy polyethylene glycol acrylate of Amisulpride are mixed, and the ammonia sulphur obtained by such preparation method must
Sharp piece is stablized, and Fast Stripping is easy, rapid-action.
The beneficial effects of the present invention are:
1, methoxy polyethylene glycol acrylate and magnesium chloride is added in the present invention on the basis of existing raw material, passes through research
It was found that obtained Amisulpride tablet stability is good, and quick can must dissolve out, drug safety and validity are improved, is kept away
Exempt from the incidence of adverse reaction.
2, the addition sequence of each raw material of strict control of the present invention, and hydroxypropyl methylcellulose is first made aqueous solution, then with
Mixture and methoxy polyethylene glycol acrylate containing Amisulpride are mixed, the ammonia sulphur obtained by such preparation method
Must sharp piece stablize, the water solubility of tablet can be significantly improved, be conducive to drug Fast Stripping in the gastrointestinal tract, improve biology
Availability.
3, bulk pharmaceutical chemicals of the invention are easy to get, and component is simple, and obtained Amisulpride piece is quickly effective, safely and effectively, product
Homogeneity and controllability are good, are conducive to absorption of human body, can take for a long time.
4, preparation method simple process of the invention is suitble to scale industrial production.
Specific embodiment
To make the objectives, technical solutions, and advantages of the present invention clearer, below in conjunction with specific embodiment, to this hair
Bright further description.
Embodiment 1
Amisulpride piece includes following each component and its weight percentage: Amisulpride 60%, lactose 8%, and crystallite is fine
Dimension element 20%, sodium carboxymethyl starch 5%, hydroxypropyl methylcellulose 2.7%, magnesium stearate 0.1%, additive 1%, the poly- second of methoxyl group
Butanediol acrylate 1%, magnesium chloride 0.2%, coating powder 2%；The additive includes that following each component and its weight percent contain
Amount: Aspartame 15%, essence 45%, sodium chloride 40%.
Amisulpride piece the preparation method comprises the following steps: raw material 1) is weighed in proportion, by Amisulpride, lactose, microcrystalline cellulose, carboxylic
Methyl starch sodium and additive are mixed to get mixture；
2) the hydroxypropyl methylcellulose aqueous solution and the poly- second two of methoxyl group that mass percentage concentration is 5-6% are added into mixture
Alcohol acrylate, the after mixing wet granulation in fluid bed granulator, grain made parameter are as follows: inlet air temperature is 110 DEG C, guarantees object
Material fluidisation completely, atomizing pressure 0.6MPa, particle obtained is dry at 55 DEG C, crosses 25 meshes；
3) magnesium stearate and magnesium chloride are sequentially added into the particle after drying, carries out tabletting after mixing, obtaining ammonia sulphur must
Sharp plain piece, Opadry gastric solubility coating powder is dissolved in water to obtain the coating solution that mass concentration is 13%, right in high-efficiency coating machine
Amisulpride plain piece is coated, and is controlled coating weight gain 2.5%, is obtained Amisulpride piece.
Embodiment 2
Amisulpride piece includes following each component and its weight percentage: Amisulpride 63%, lactose 8%, and crystallite is fine
Dimension element 15%, sodium carboxymethyl starch 4%, hydroxypropyl methylcellulose 2%, magnesium stearate 0.3%, additive 0.8%, the poly- second of methoxyl group
Butanediol acrylate 2.5%, magnesium chloride 0.4%, coating powder 3%；The additive includes following each component and its weight percent
Content: Aspartame 10%, essence 40%, sodium chloride 50%.
Amisulpride piece the preparation method comprises the following steps: raw material 1) is weighed in proportion, by Amisulpride, lactose, microcrystalline cellulose, carboxylic
Methyl starch sodium and additive are mixed to get mixture；
2) the hydroxypropyl methylcellulose aqueous solution and the poly- second two of methoxyl group that mass percentage concentration is 5-6% are added into mixture
Alcohol acrylate, the after mixing wet granulation in fluid bed granulator, grain made parameter are as follows: inlet air temperature is 110 DEG C, guarantees object
Material fluidisation completely, atomizing pressure 0.65MPa, particle obtained is dry at 60 DEG C, crosses 30 meshes；
3) magnesium stearate and magnesium chloride are sequentially added into the particle after drying, carries out tabletting after mixing, obtaining ammonia sulphur must
Sharp plain piece, Opadry gastric solubility coating powder is dissolved in water to obtain the coating solution that mass concentration is 15%, right in high-efficiency coating machine
Amisulpride plain piece is coated, and is controlled coating weight gain 3%, is obtained Amisulpride piece.
Embodiment 3
Amisulpride piece includes following each component and its weight percentage: Amisulpride 70%, lactose 4%, and crystallite is fine
Dimension element 15.5%, sodium carboxymethyl starch 3%, hydroxypropyl methylcellulose 1%, magnesium stearate 0.5%, additive 0.5%, methoxyl group are poly-
Ethylene glycol acrylate 3%, magnesium chloride 0.5%, coating powder 2%；The additive includes following each component and its weight percent
Content: Aspartame 10%, essence 40%, sodium chloride 50%.
Amisulpride piece the preparation method comprises the following steps: raw material 1) is weighed in proportion, by Amisulpride, lactose, microcrystalline cellulose, carboxylic
Methyl starch sodium and additive are mixed to get mixture；
2) the hydroxypropyl methylcellulose aqueous solution and the poly- second two of methoxyl group that mass percentage concentration is 5-6% are added into mixture
Alcohol acrylate, the after mixing wet granulation in fluid bed granulator, grain made parameter are as follows: inlet air temperature is 110 DEG C, guarantees object
Material fluidisation completely, atomizing pressure 0.5MPa, particle obtained is dry at 50 DEG C, crosses 20 meshes；
3) magnesium stearate and magnesium chloride are sequentially added into the particle after drying, carries out tabletting after mixing, obtaining ammonia sulphur must
Sharp plain piece, Opadry gastric solubility coating powder is dissolved in water to obtain the coating solution that mass concentration is 10%, right in high-efficiency coating machine
Amisulpride plain piece is coated, and is controlled coating weight gain 2%, is obtained Amisulpride piece.
Comparative example 1
Amisulpride piece includes following each component and its weight percentage: Amisulpride 68%, lactose 8%, and crystallite is fine
Dimension element 15.9%, sodium carboxymethyl starch 4%, hydroxypropyl methylcellulose 2%, magnesium stearate 0.3%, additive 0.8%；The addition
Agent includes following each component and its weight percentage: Aspartame 10%, essence 40%, sodium chloride 50%.
Amisulpride piece the preparation method comprises the following steps: raw material 1) is weighed in proportion, by Amisulpride, lactose, microcrystalline cellulose, carboxylic
Methyl starch sodium and additive are mixed to get mixture；
2) the hydroxypropyl methylcellulose aqueous solution that mass percentage concentration is 5-6% is added into mixture, exists after mixing
Wet granulation in fluid bed granulator, grain made parameter are as follows: inlet air temperature is 110 DEG C, guarantees that material fluidizes completely, atomizing pressure is
0.65MPa, particle obtained is dry at 60 DEG C, crosses 30 meshes；
3) magnesium stearate is sequentially added into the particle after drying, carries out tabletting after mixing, obtains Amisulpride plain piece, Europe
Bar it is dissolved in water to obtain the coating solution that mass concentration is 15% for gastric solubility coating powder, to Amisulpride element in high-efficiency coating machine
Piece is coated, and is controlled coating weight gain 3%, is obtained Amisulpride piece.
Comparative example 2
Using in number of patent application CN201710118831.2 raw material and method prepare Amisulpride piece.
Amisulpride piece that embodiment 1-3 and comparative example 1-2 are obtained carries out dissolution test: using dissolution method (in
Two the second methods of annex XC of state's pharmacopeia version in 2010), it takes water as a solvent, revolving speed is 50 revs/min, and temperature is 37.0 ± 0.5 DEG C
It operates according to methods, at 10 minutes, taking liquid 10ml, while the water of equivalent is supplemented, and medical fluid is crossed to 0.45 μm of membrane filtration, it is ultraviolet
Spectrophotometry is measured, and is calculated dissolution rate, be the results are shown in Table 1.
1 dissolution determination result of table
| Embodiment | Dissolution rate (%) |
| Embodiment 1 | 95.3 |
| Embodiment 2 | 96.4 |
| Embodiment 3 | 94.8 |
| Comparative example 1 | 88.2 |
| Comparative example 2 | 84.2 |
It can be seen that the Amisulpride piece that the present invention obtains and the Amisulpride piece that comparative example obtains from the data in table 1
At 10 minutes accumulate dissolution rate be more than 90%, and in comparative example Amisulpride piece accumulation dissolution rate 90% with
Under, illustrate steadily can quickly dissolve out using the Amisulpride piece that raw material and method of the invention obtain, this feature is shown
Tablet prepared by the present invention can make drug steady quick release in vivo, play curative effect of medication quickly, and effectively
Avoid drug peak valley phenomenon, reduce because blood concentration it is excessively high caused by adverse reaction.
Amisulpride tablet stability is investigated
Influence factor test: the Amisulpride piece that embodiment 1-3 and comparative example 1-2 are obtained sets illumination (4500LX respectively
± 500LX), high temperature (60 DEG C), place under the conditions of high humidity (92.5%), respectively at the 5th day, the related substance of 10 days sample detections
(total impurities) the results are shown in Table 2.
The related substance (%) of 2 influence factor testing inspection of table
Accelerated test: setting 40 DEG C of temperature by commercially available back for the Amisulpride piece that embodiment 1-3 and comparative example 1-2 are obtained,
It is placed 6 months in the climatic chamber of relative humidity 75%, and in the related substance of 6 the end of month sample detections, the results are shown in Table 3:
The related substance of 3 accelerated test of table compares (%)
| Time (moon) | Embodiment 1 | Embodiment 2 | Embodiment 3 | Comparative example 1 | Comparative example 2 |
| 0 | 0.10 | 0.10 | 0.10 | 0.10 | 0.12 |
| 6 | 0.11 | 0.12 | 0.11 | 0.22 | 0.20 |
In the test of Amisulpride piece influence factor and accelerated test, the character and content of tablet do not change substantially, by
The test result of table 2 and table 3 can be seen that the related substance of Amisulpride piece of the invention far below comparative example.Illustrate the present invention
Prepared Amisulpride piece can be improved the stability of drug, extend the storage life of drug.
Claims (9)
1. a kind of Amisulpride piece, which is characterized in that including following each component and its weight percentage: Amisulpride 60-
70%, lactose 4-8%, microcrystalline cellulose 15-20%%, sodium carboxymethyl starch 3-5%, hydroxypropyl methylcellulose 1-3%, stearic acid
Magnesium 0.1-0.5%, additive 0.5-1%, methoxy polyethylene glycol acrylate 1-3%, magnesium chloride 0.2-0.5%, coating powder
2-3%.
2. Amisulpride piece as described in claim 1, which is characterized in that including following each component and its weight percentage: ammonia
Sulphur must benefit 63%, lactose 8%, microcrystalline cellulose 15%, sodium carboxymethyl starch 4%, hydroxypropyl methylcellulose 2%, magnesium stearate
0.3%, additive 0.8%, methoxy polyethylene glycol acrylate 2.5%, magnesium chloride 0.4%, coating powder 3%.
3. Amisulpride piece as claimed in claim 1 or 2, which is characterized in that the additive includes following each component and its again
Measure percentage composition: Aspartame 10-15%, essence 40-45%, sodium chloride 40-50%.
4. Amisulpride piece as claimed in claim 3, which is characterized in that the essence is orange taste essence or honey peach taste essence.
5. the preparation method of Amisulpride piece as described in claim 1, which comprises the following steps:
1) raw material is weighed in proportion, and Amisulpride, lactose, microcrystalline cellulose, sodium carboxymethyl starch and additive are mixed to get
Mixture；
2) hydroxypropyl methylcellulose aqueous solution and methoxy polyethylene glycol acrylate are added into mixture, after mixing wet process
Granulation, particle drying obtained cross 20-30 mesh；
3) magnesium stearate and magnesium chloride are sequentially added into the particle after drying, carries out tabletting after mixing, obtained Amisulpride
Plain piece is coated, and obtains Amisulpride piece.
6. the preparation method of Amisulpride piece as claimed in claim 5, which is characterized in that hydroxypropyl methylcellulose described in step 2)
The mass percentage concentration of aqueous solution is 5-6%.
7. the preparation method of Amisulpride piece as claimed in claim 6, which is characterized in that the hydroxypropyl methylcellulose aqueous solution
Preparation method are as follows: by the suitable boiling water stirring and dissolving of hydroxypropyl methylcellulose, cold water is then added mass percentage concentration is made and be
The hydroxypropyl methylcellulose aqueous solution of 5-6%.
8. the preparation method of Amisulpride piece as described in claim 5 or 6, which is characterized in that the method for the step 3) coating
Are as follows: coating powder is dissolved in water to obtain the coating solution that mass concentration is 10-15%, to Amisulpride plain piece in high-efficiency coating machine
It is coated.
9. the preparation method of Amisulpride piece as claimed in claim 8, which is characterized in that the coating powder is Opadry gastric solubility
Coating powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811245257.8A CN109010300A (en) | 2018-10-24 | 2018-10-24 | A kind of Amisulpride piece and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811245257.8A CN109010300A (en) | 2018-10-24 | 2018-10-24 | A kind of Amisulpride piece and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109010300A true CN109010300A (en) | 2018-12-18 |
Family
ID=64614142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811245257.8A Pending CN109010300A (en) | 2018-10-24 | 2018-10-24 | A kind of Amisulpride piece and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109010300A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10800738B2 (en) | 2017-12-05 | 2020-10-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CN112089698A (en) * | 2020-10-23 | 2020-12-18 | 江苏阿尔法药业有限公司 | Amisulpride tablet and preparation method thereof |
| US10874639B2 (en) | 2017-12-05 | 2020-12-29 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| US11160758B2 (en) | 2019-06-04 | 2021-11-02 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1842331A (en) * | 2003-07-09 | 2006-10-04 | 赛诺菲-安万特 | Novel solid pharmaceutical composition comprising amisulpride |
| US20090238854A1 (en) * | 2004-08-05 | 2009-09-24 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
| WO2010023690A2 (en) * | 2008-08-28 | 2010-03-04 | Torrent Pharmaceuticals Ltd. | Prolonged release formulation of amisulpride |
| CN107126422A (en) * | 2017-03-02 | 2017-09-05 | 河北龙海药业有限公司 | A kind of Amisulpride tablet and preparation method thereof |
-
2018
- 2018-10-24 CN CN201811245257.8A patent/CN109010300A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1842331A (en) * | 2003-07-09 | 2006-10-04 | 赛诺菲-安万特 | Novel solid pharmaceutical composition comprising amisulpride |
| US20090238854A1 (en) * | 2004-08-05 | 2009-09-24 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
| WO2010023690A2 (en) * | 2008-08-28 | 2010-03-04 | Torrent Pharmaceuticals Ltd. | Prolonged release formulation of amisulpride |
| CN107126422A (en) * | 2017-03-02 | 2017-09-05 | 河北龙海药业有限公司 | A kind of Amisulpride tablet and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张天胜主编: "《表面活性剂应用技术》", 30 September 2001, 化学工业出版社 * |
| 谢麟等: "《兽用药剂技术手册》", 31 October 1993, 广西科学技术出版社 * |
| 金一丰等: ""聚乙二醇单甲醚甲基丙烯酸酯的合成工艺研究"", 《精细与专用化学品》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10800738B2 (en) | 2017-12-05 | 2020-10-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| US10874639B2 (en) | 2017-12-05 | 2020-12-29 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| US11370753B2 (en) | 2017-12-05 | 2022-06-28 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| US11517558B2 (en) | 2017-12-05 | 2022-12-06 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| US11767293B2 (en) | 2017-12-05 | 2023-09-26 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| US11160758B2 (en) | 2019-06-04 | 2021-11-02 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| US11654113B2 (en) | 2019-06-04 | 2023-05-23 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| CN112089698A (en) * | 2020-10-23 | 2020-12-18 | 江苏阿尔法药业有限公司 | Amisulpride tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109010300A (en) | A kind of Amisulpride piece and preparation method thereof | |
| WO2017114227A1 (en) | Dapagliflozin and metformin complex extended release tablet and preparation method thereof | |
| CN101574323B (en) | Migltol microcapsule tablet and preparation method thereof | |
| CN107049981A (en) | A kind of quick-release Amisulpride pharmaceutical composition and preparation method thereof | |
| CN103356489B (en) | Proton pump inhibitor enteric coated pellet and preparation and preparation method thereof | |
| CN101912375A (en) | Metformin controlled release tablet | |
| JP2016098179A (en) | Production method of spray dry solution and solid dispersion using hypromellose acetate succinate | |
| JP2017186331A (en) | Hypromellose acetate succinate powders having excellent clarity and color of solution and production method thereof, as well as each production method of solid dispersion composition, coating composition, drug-containing particles, and solid preparations | |
| CN103784426B (en) | Molten membrane of Aripiprazole mouth and preparation method thereof | |
| CN102600132A (en) | Oral preparation containing amisulpride | |
| CN115025066B (en) | Preparation method of traditional Chinese medicine slow-release particles with stable quality and capable of resisting diarrhea of piglets | |
| RU2444359C1 (en) | Pharmaceutical composition with 2-ethyl-6-methyl-3-hydroxypyridine succinate for oral administration and method for preparing it | |
| CN105343028A (en) | Medicine composition with norfloxacin and method for preparing medicine composition | |
| CN104146977B (en) | A kind of pantoprazole sodium enteric tablet and preparation method thereof | |
| CN108283628A (en) | A kind of anticancer drug microcapsule formulation and preparation method thereof | |
| CN113616613A (en) | Metformin-glipizide compound tablet for treating diabetes and preparation method thereof | |
| CN110354093B (en) | Mosapride citrate pharmaceutical composition | |
| CN109758431A (en) | A kind of metformin hydrochloride tablet and preparation method thereof | |
| CN108261409A (en) | A kind of combination of oral medication of dabigatran etcxilate and preparation method thereof | |
| CN108379237A (en) | A kind of medicament microcapsule preparation for the treatment of of urinary tract infections and preparation method thereof | |
| CN106176642B (en) | A kind of Disket and preparation method thereof for treating respiratory disease | |
| JP2006257068A (en) | High content terbinafine hydrochloride tablet and method for producing the same | |
| CN109330985A (en) | A kind of vitamin C vaginal tablets and preparation method thereof | |
| CN108159009A (en) | A kind of preparation method of high stability White staphylococcus tablet | |
| CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181218 |